The Trump administration reignited the U.S. drug pricing debate by signing a sweeping Executive Order on May 12, introducing a “Most Favored Nation” (MFN) pricing framework. This policy seeks to ...

Aside from pricing changes, the impacts that MFN could have on the US market could have global reverberations. Peter Rubin, executive director of No Patient Left Behind, spoke with Pharmaceutical ...

Ron Lanton, Partner, Lanton Law, outlines how the MFN executive order may face significant legal challenges from the pharmaceutical industry, citing concerns over due process, intellectual property, ...

AstraZeneca has become the second pharma group, after Pfizer, to reach an agreement with the Trump administration on a deal to reduce the price of its medicines in the US. President Trump said AZ "is ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

AstraZeneca will offer drugs at reduced prices in the US through the TrumpRx.gov platform, launching in 2026. The agreement aims to make prescriptions more affordable for low-income patients, ...

I will conclude this series of posts by considering the variants of MFN that affect the way strict scrutiny is applied. MFN-6, ubiquitous in the Covid cases, makes strict scrutiny impossible to ...

In a recent transaction, MFN Partners LP, a significant shareholder in RXO Inc. (NYSE:RXO), has increased their stake in the company with the purchase of shares valued at approximately $2.7 million.